Metagenomi, Inc. - Common Stock (MGX)

The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

OpenAI CEO Sam Altman regrets underestimating Elon Musk's potential abuse of power to block OpenAI's $500B Stargate deal. Tensions also rise with Microsoft.

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.

Positive data from clinical trials, earnings readouts, M&A speculation and new research drew heavy interest from retail traders on Stocktwits for these tickers for the week ended March 14, 2025.

There's a lot for investors to talk about.

MGX stock results show that Metagenomi beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

MGX stock results show that Metagenomi missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

Moderna reports Q1 loss, beating sales estimates amidst declining COVID-19 vaccine demand. Cost-saving measures drive optimism for investors. CEO Stéphane Bancel eyes strategic investments. Guidance reaffirms $4 billion sales target for 2024.

Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion.

A bumpy start can't detract from this company's strong balance sheet.

Kyverna Therapeutics raised almost $320 million in its initial public offering, which was priced above the marketed range. Backed by Gilead Sciences, the company's offering was the second largest for a drug developer this year.